Is CHA2DS2-VASc Score different between patients with and without atrial fibrillation suffering from peripheral arterial embolism?

Objective: CHA2DS2-VASc is a validated , straightforward and practical stratification of thromboembolic risk score for non-valvular atrial fibrillation (NVAF). However it is usually used for stroke. In this trial we aim to compare the CHA2DS2-VASc score between patients with and without AF suffering from peripheral arterial embolism (PAE). Materials and Methods: We retrospectively evaluated the data registries of 150 patients who admitted to hospital due to PAE between January 2011- December 2016. CHA2DS2-VASc score was calculated for each patient Results: Atrial fibrillation was detected 59% of patients. Patients with AF were elder, more often female gender, hypertension, heart failure, hyperlipidemia, stroke and transient ischemic attack (p<0.05). The rate of prior PAE was similar between two groups (p>0.05). Patients with AF had higher CHA2DS2-VASc score then those without AF (5.1±1.7 vs 3.5±1.8 p<0.001). The rate of the patients with a CHA2DS2-VASc score 1-3 was higher in non-AF group (41% vs 23% p=0.017. However the rate of the patients with a CHA2DS2-VASc score score 7-9 was higher in AF group (28% vs 6% p<0.001). In-hospital mortality was similar between groups (14% vs 7% p=0.235). Conclusion: Although AF patients had higher thromboembolic risk level based on CHA2DS2-VASc score. The rate of prior PAE rate was similar between AF and non-AF groups